Hematological Oncology最新文献

{"title":"Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma","authors":"Jiangfang Feng,&nbsp;Yue Fei,&nbsp;Meng Gao,&nbsp;Xiangrui Meng,&nbsp;Dongfeng Zeng,&nbsp;Dehui Zou,&nbsp;Haige Ye,&nbsp;Yun Liang,&nbsp;Xiuhua Sun,&nbsp;Rong Liang,&nbsp;Hui Zhou,&nbsp;Xianhuo Wang,&nbsp;Huilai Zhang","doi":"10.1002/hon.3268","DOIUrl":"https://doi.org/10.1002/hon.3268","url":null,"abstract":"<p>Mantle cell lymphoma (MCL) is an uncommon and incurable B-cell lymphoma subtype that has an aggressive course. Hepatitis B virus (HBV) infection has been associated with an increased risk for B-cell lymphomas, and is characterized by distinct clinical and genetic features. Here, we showed that 9.5% of MCL Chinese patients were hepatitis B surface antigen positive (HBsAg⁺). Compared to HBsAg-negative (HBsAg⁻) patients, HBsAg⁺ MCL patients had a greater incidence of elevated lactate dehydrogenase (LDH), but no difference was observed in the other clinical characteristics, including sex, age, ECOG ps, Ann Arbor stage, MIPI, extranodal involvement and Ki-67. The HD-AraC (high-dose cytarabine) regimen was the main first-line induction regimen for younger HBsAg⁺ patients, and cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) were used for elderly patients. HBsAg seropositivity was associated with a significantly shorter PFS than HBsAg seronegativity when patients were treated with rituximab or CHOP-based regimens. Compared with CHOP, the HD-AraC regimen was associated with longer PFS in HBsAg⁺ patients. Treatment with a Bruton tyrosine kinase inhibitor (BTKi) alone can also cause HBV reactivation. Among the 74 patients who underwent targeted deep sequencing (TDS), the nonsynonymous mutation load of HBsAg⁺ MCL patients was greater than that of HBsAg⁻ MCL patients. HDAC1, TRAF5, FGFR4, SMAD2, JAK3, SMC1A, ZAP70, BLM, CDK12, PLCG2, SMO, TP63, NF1, PTPR, EPHA2, RPTOR and FIP1L1 were significantly enriched in HBsAg⁺ MCL patients.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140649543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience","authors":"Vittorio Ruggero Zilioli,&nbsp;Emanuele Cencini,&nbsp;Sonya De Lorenzo,&nbsp;Luca Pezzullo,&nbsp;Michele Merli,&nbsp;Flavia Rivellini,&nbsp;Cristina Muzi,&nbsp;Barbieri Emiliano,&nbsp;Luigi Marcheselli,&nbsp;Stefano Luminari","doi":"10.1002/hon.3273","DOIUrl":"https://doi.org/10.1002/hon.3273","url":null,"abstract":"<p>Few data are known regarding the use of interim positron emission tomography (iPET) after the first two cycles (iPET2) of chemotherapy in treatment-naïve classical Hodgkin lymphoma (cHL) in routine clinical practice, and about the real-life adoption of intensification strategies for iPET positive patients. We conducted a multicenter retrospective study on cHL to investigate the use of iPET in the real-life setting, its prognostic role and outcomes of patients early shifted to intensification. Six hundreds and forty-one patients were enrolled (62% had advanced stage). iPET2 was positive in 89 patients (14%) including 8.7% and 17% early and advanced stage patients, respectively (<i>p</i> = 0.003). Among iPET 2 positive cases treatment was immediately modified in 19 cases; in 14 cases treatment was modified after an additional positive iPET4. Overall 56 iPET2 positive patients never received intensified therapies. Most frequently used intensified therapy was autologous stem cell transplantation followed by BEACOPP. After a median follow-up of 72 months, the 5-year progression-free survival (PFS) was 82% with iPET2 positive patients showing a worse PFS compared with iPET2 negative cases: 31% versus 85%. Focusing on advanced stage patients with a positive iPET2, the 5-year PFS was 59% for patients shifted to intensified therapy at any time point versus 61% for patients who never received intensified therapy. Our study confirmed the higher curability of naïve cHL patients in a real-world setting, and the prognostic role of iPET2 in this setting. A poor adherence to response-adapted strategy which however did not translate into a difference in patient outcomes.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3273","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140641746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to reply to “successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients—A Czech multicenter experience”: A case series of SARS-CoV-2 Omicron infection and aggressive lymphoma in the Sotrovimab era","authors":"","doi":"10.1002/hon.3267","DOIUrl":"https://doi.org/10.1002/hon.3267","url":null,"abstract":"<p>Cassin R, Rampi N, Fidanza C, et al. Reply to “successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients—A Czech multicenter experience”: A case series of SARS-CoV-2 Omicron infection and aggressive lymphoma in the Sotrovimab era. Hematol Oncol. 2023; 41 (1):213-217. https://doi.org/10.1002/hon.3079.</p><p>In the article, the first name of the third author was abbreviated. The correct author name is Cecilia Anna Fidanza instead of Fidanza C.</p><p>We apologize for this error.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3267","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140641747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Future perspectives of radiation therapy for Hodgkin Lymphoma: Risk-adapted, response-adapted, and safer than before","authors":"Jessica Saddi,&nbsp;Amelia Barcellini,&nbsp;Manuel Gotti,&nbsp;Alessandro Mazzacane,&nbsp;Alessandra Tolva,&nbsp;Tanja Lazic,&nbsp;Luca Arcaini,&nbsp;Marco Zecca,&nbsp;Ester Orlandi,&nbsp;Andrea Riccardo Filippi","doi":"10.1002/hon.3269","DOIUrl":"https://doi.org/10.1002/hon.3269","url":null,"abstract":"<p>Classical Hodgkin lymphoma is a lymphoproliferative disease with a good prognosis mainly seen in young people. Nevertheless secondary malignancy, cardiac disease and infertility may affect the long survivors with significant impact on quality of life, morbidity and overall survival. In the last decades several treatment strategies were evaluated to reduce the toxicity of first line treatment such as avoiding radiotherapy or its reduction in terms of dosage and extension. Many trials including interim Positron Emission Tomography evaluation fail to compare efficacy between combined modality treatment versus chemotherapy alone in particular in early stage disease. In this review we analyze which subset of patients could take advantage from proton therapy in terms of toxicity and cost effectiveness.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3269","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140633826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovery Science highlights from the 17th International Conference on Malignant Lymphoma","authors":"Gabriela Forestieri,&nbsp;Joyce Marques de Almeida,&nbsp;Sara Napoli,&nbsp;Deborah Piffaretti,&nbsp;Chiara Tarantelli,&nbsp;Fangwen Zhang,&nbsp;Afua Adjeiwaa Mensah","doi":"10.1002/hon.3275","DOIUrl":"https://doi.org/10.1002/hon.3275","url":null,"abstract":"<p>Since its inception over 4 decades ago, the International Conference on Malignant Lymphoma (ICML) has steadily grown to become the leading international forum for lymphoma experts. Now with a biennial occurrence and more than 3000 participants, the ICML provides a unique opportunity for lymphoma clinicians, healthcare workers and scientists to come together and discuss novel data gleaned from discovery science, translational research, and clinical research efforts. Many pivotal findings in the lymphoma research community were first reported at ICML meetings and some of these have driven practice-changing approaches in lymphoma patient care.</p><p>As lymphoma scientists working at the Institute of Oncology Research in Bellinzona, Switzerland, we are proud to be involved in the ICML. In collaboration with Women in Lymphoma, we are excited to present to you our selected <i>Discovery Science highlights</i> from the 17th ICML meeting. Our aim is for these highlights to complement the clinical take-home messages presented at the <i>17-ICML highlights</i> session and as such champion the importance of collaborative research which combines the expertise of clinical and non-clinical investigators, for the effective prevention, diagnosis and treatment of lymphomas.</p><p>Over the years, the work of a multitude of lymphoma researchers together with the emergence of new technologies, have resulted in a richer understanding of the molecular features that initiate and support lymphomagenesis. Laura Pasqualucci (New York, USA), is aptly recognised as having made seminal contributions to our understanding of lymphoma biology and as such, a number of her team's findings featured in her <i>Meet the Professor</i> session,<span>¹</span> which focused on the role of the germinal center (GC) in the genesis of lymphomas. After giving an authoritative overview of the genetic, epigenetic and microenvironmental perturbations involved in the pathogenesis of lymphomas originating from the GC, she explained how she and Riccardo Dalla-Favera (New York, USA), embarked on opening the “big black box” that is the non-coding human genome to better study GC-derived lymphomas. Their investigations revealed that superenhancers (SE) were frequently hypermutated in diffuse large B cell lymphomas (DLBCLs). Over 90% of DLBCLs were found to harbor at least two mutations within SE regions thus indicating a selective pressure to acquire mutations in these regulatory domains. The activation induced cytidine deaminase, AID, was identified as a central player in the introduction of these mutations and the SE of key genes involved in lymphomagenesis were among those targeted. Working in the lab of Riccardo Dalla-Favera and Laura Pasqualucci, Elodie Bal, whose investigations uncovered this frequent targeting of SE in DLBCL, described her findings in more detail in two different sessions, <i>Epigenetic mechanisms and targeted therapies in B- and T-cell lymphomas</i> and <i>Lymphoma ","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3275","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140633827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes after treating advanced mantle cell lymphoma in a low-income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation","authors":"José Carlos Jaime-Pérez,&nbsp;Marcela Hernández-Coronado,&nbsp;Mariana González-Treviño,&nbsp;Renata V. Barragán-Longoria,&nbsp;Eugenia M. Ramos-Dávila,&nbsp;David Gómez-Almaguer","doi":"10.1002/hon.3271","DOIUrl":"https://doi.org/10.1002/hon.3271","url":null,"abstract":"","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140546857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203","authors":"Takashi Watanabe,&nbsp;Yoshihiro Matsuno,&nbsp;Masashi Wakabayashi,&nbsp;Dai Maruyama,&nbsp;Kazuhito Yamamoto,&nbsp;Nobuko Kubota,&nbsp;Kazuyuki Shimada,&nbsp;Kohsuke Asagoe,&nbsp;Motoko Yamaguchi,&nbsp;Kiyoshi Ando,&nbsp;Michinori Ogura,&nbsp;Junya Kuroda,&nbsp;Youko Suehiro,&nbsp;Kunihiro Tsukasaki,&nbsp;Kensei Tobinai,&nbsp;Hirokazu Nagai","doi":"10.1002/hon.3272","DOIUrl":"https://doi.org/10.1002/hon.3272","url":null,"abstract":"<p>Follicular lymphoma (FL) is an indolent lymphoma that becomes aggressive due to histological transformation (HT), leading to reduced survival. Patients with FL have different clinical courses and various treatment options. Some patients exhibit shorter survival and experience disease progression within 24 months of diagnosis/treatment (POD24); the optimal treatment remains an unmet needs. Thus, identifying factors that predict shorter survival is essential to stratify treatment and prolong the survival of patients with FL. To analyze risk factors for POD24 and HT in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as first-line treatment, we performed this post-hoc analysis of patients with advanced indolent B-cell lymphoma in a randomized clinical trial wherein six cycles of R-CHOP were administered every 2–3 weeks. The primary analysis showed no differences in outcomes, which enabled the analysis of 248 patients with FL, assigned to two arms. All histopathological specimens from the 300 enrolled patients were reviewed by three expert hematopathologists. Multivariable analysis implicated Follicular Lymphoma International Prognostic Index (FLIPI) intermediate (odds ratio [OR] 2.531, 95% confidence interval [CI] 0.676–9.466) and high- (OR 2.236, 95% CI 0.160–31.226) risks, B symptoms (OR 2.091, 95% CI 0.747–5.851), and grade 3A (G3A) (OR 1.833, 95% CI 0.634–5.299) as risk factors for POD24. Furthermore, multivariable analysis through a median follow-up of 15.9 years implicated G3A (OR 2.628, 95% CI 0.806–8.575) and high-risk FLIPI (OR 4.401, 95% CI 0.186–104.377) as risk factors for HT. However, an analysis limited to the first 10 years revealed that the prognostic factors elucidated from the longer-term analysis had a greater impact on HT. G3A and high-risk FLIPI may independently predict POD24 and HT, thereby informing treatment stratification of patients with untreated advanced-stage FL in future trials, particularly to address the unmet needs of patients with POD24.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.3272","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140541039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis","authors":"Maria Livia Del Giudice,&nbsp;Sara Galimberti,&nbsp;Gabriele Buda","doi":"10.1002/hon.3270","DOIUrl":"https://doi.org/10.1002/hon.3270","url":null,"abstract":"<p>Light chain amyloidosis is a rare disease caused by clonal plasma cells in the bone marrow generating an excessive amount of immunoglobulin light chains. These chains misfold and produce insoluble fibrils that deposit in various organs, including the heart, kidneys, liver, nervous system, and digestive tract. Life expectancy and symptoms during the course of the disease vary depending on which and how many organs are affected. Targeted plasma cell therapy has significantly advanced the clinical management of amyloidosis, with ongoing progress. However, current clinical studies are investigating innovative targets, drug combinations and treatment strategies to improve therapeutic outcomes by minimizing adverse effects and refining patient prognosis in these challenging hematological conditions. In this paper, we review the state of the art regarding the use of anti-amyloid antibodies, as a revolutionary and innovative approach in the current scenario of amyloid treatment.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140537830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children's leukemia group","authors":"Xinyu Li,&nbsp;Shaofen Lin,&nbsp;Ning Liao,&nbsp;Huirong Mai,&nbsp;Xingjiang Long,&nbsp;Lili Liu,&nbsp;Beiyan Wu,&nbsp;Qiwen Chen,&nbsp;Qian Kong,&nbsp;Xianling Kong,&nbsp;Lixia Liu,&nbsp;Jiayue Qin,&nbsp;Jianpei Fang,&nbsp;Dunhua Zhou","doi":"10.1002/hon.3265","DOIUrl":"https://doi.org/10.1002/hon.3265","url":null,"abstract":"<p>The next-generation sequencing technologies application discovers novel genetic alterations frequently in pediatric acute lymphoblastic leukemia (ALL). RAS signaling pathway mutations at the time of relapse ALL frequently appear as small subclones at the time of onset, which are considered as the drivers in ALL relapse. Whether subclones alterations in the RAS signaling pathway should be considered for risk group stratification of ALL treatment is not decided yet. In this work, we investigate the <i>RAS</i> signaling pathway mutation spectrum and the related prognosis in pediatric ALL. We employed an NGS panel comprising 220 genes. NGS results were collected from 202 pediatric ALL patients. 155 patients (76.7%) harbored at least one mutation. The incidences of <i>RAS</i> signaling pathway mutations are different significantly between T-ALL and B-ALL. In B-ALL, the <i>RAS</i> pathway is mostly involved, and <i>NRAS</i> (17.6%), <i>KRAS</i> (22.7%), and <i>PTPN11</i> (7.7%) were the three most frequently mutated genes. Co-occurring mutations of <i>CREBBP</i> and <i>NRAS</i>, <i>FLT3</i>, or <i>PTPN11</i> (<i>p</i> = 0.002, <i>p</i> = 0.009, and <i>p</i> = 0.003, respectively) were found in this cohort. The 3-year RFS rates for the <i>RAS</i> signaling pathway mutation-positive and negative cases was 76.5 % versus 89.7 % (<i>p</i> = 0.012). Four cases relapsed in the lately 3 years were <i>RAS</i> signaling pathway mutation-positive. <i>RAS</i> signaling pathway mutation is an important biomarker for poorer relapse-free survival in pediatric B-ALL patients despite good early MRD levels.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 3","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140343061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia","authors":"Yuan Sun,&nbsp;Xu Wang,&nbsp;Wen-Min Chen,&nbsp;Yue Hao,&nbsp;Ling-Di Li,&nbsp;Jin-Ying Li,&nbsp;Kai Sun,&nbsp;Zong-Yan Shi,&nbsp;Hao Jiang,&nbsp;Qian Jiang,&nbsp;Xiao-Jun Huang,&nbsp;Ya-Zhen Qin","doi":"10.1002/hon.3264","DOIUrl":"10.1002/hon.3264","url":null,"abstract":"<p>In addition to RUNX1::RUNX1T1 transcript levels, measurable residual disease monitoring using KIT mutant (KIT^mut) DNA level is reportedly predictive of relapse in <i>t</i> (8; 21) acute myeloid leukemia (AML). However, the usefulness of KIT^mut transcript levels remains unknown. A total of 202 bone marrow samples collected at diagnosis and during treatment from 52 <i>t</i> (8; 21) AML patients with KIT^mut (D816V/H/Y or N822K) were tested for KIT^mut transcript levels using digital polymerase chain reaction. The individual optimal cutoff values of KIT^mut were identified by performing receiver operating characteristics curve analysis for relapse at each of the following time points: at diagnosis, after achieving complete remission (CR), and after Course 1 and 2 consolidations. The cutoff values were used to divide the patients into the KIT^mut-high (KIT_H) group and the KIT^mut-low (KIT_L) group. The KIT_H patients showed significantly lower relapse-free survival (RFS) and overall survival (OS) rates than the KIT_L patients after Course 1 consolidation (<i>p</i> = 0.0040 and 0.021, respectively) and Course 2 consolidation (<i>p</i> = 0.018 and 0.011, respectively) but not at diagnosis and CR. The &lt;3-log reduction in the RUNX1::RUNX1T1 transcript levels after Course 2 consolidation was an independent adverse prognostic factor for RFS and OS. After Course 2 consolidation, the KIT_H patients with &gt;3-log reduction in the RUNX1::RUNX1T1 transcript levels (11/45; 24.4%) had similar RFS as that of patients with &lt;3-log reduction in the RUNX1::RUNX1T1 transcript levels. The combination of KIT^mut and RUNX1::RUNX1T1 transcript levels after Course 2 consolidation may improve risk stratification in <i>t</i> (8; 21) AML patient with KIT mutation.</p>","PeriodicalId":12882,"journal":{"name":"Hematological Oncology","volume":"42 2","pages":""},"PeriodicalIF":3.3,"publicationDate":"2024-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140068334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}